DOI: 10.6084/m9.figshare.30499508.v1
title: Supplementary data: Considerations for emulations of randomized controlled trials using real-world data: learnings from an emulation of MONALEESA-2

description: <b>These are peer-reviewed supplementary materials for the article</b><b> </b><b>'</b><b>Considerations for emulations of </b><b>randomized controlled trials using </b><b>real-world data: learnings from an </b><b>emulation of MONALEESA-2</b><b>'</b><b> </b><b>published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><b>Appendix Table 1:</b> Operationalization of trial inclusion criteria<b>Appendix Table 2:</b> Operationalization of trial exclusion criteria<b>Appendix Table 3:</b> Absolute standardized differences after IPTW and PS matching for the primary analysis of ribociclib plus letrozole vs. contemporaneous letrozole<b>Appendix Table 4:</b> Absolute standardized differences after IPTW and PS matching for the subgroup analysis of ribociclib plus letrozole vs. contemporaneous letrozole<b>Appendix Table 5:</b> Absolute standardized differences after IPTW and PS matching for the primary analysis of ribociclib plus letrozole vs. letrozole historical cohort 1<b>Appendix Table 6:</b> Absolute standardized differences after IPTW and PS matching for the primary analysis of ribociclib plus letrozole vs. letrozole historical cohort 2<b>Appendix Figure 1:</b> Weighted Kaplan-Meier curve for the primary analysis of ribociclib plus letrozole vs. contemporaneous letrozole<b>Appendix Figure 2:</b> Matched Kaplan-Meier curve for the primary analysis of ribociclib plus letrozole vs. contemporaneous letrozole<b>Appendix Figure 3:</b> Weighted Kaplan-Meier curve for the primary analysis of ribociclib plus letrozole vs. letrozole historical cohort 1<b>Appendix Figure 4:</b> Matched Kaplan-Meier curve for the primary analysis of ribociclib plus letrozole vs. letrozole historical cohort 1<b>Appendix Figure 5: </b>Weighted Kaplan-Meier curve for the primary analysis of ribociclib plus letrozole vs. letrozole historical cohort 2<b>Appendix Figure 6:</b> Matched Kaplan-Meier curve for the primary analysis of ribociclib plus letrozole vs. letrozole historical cohort 2<b>Aim:</b> The eligibility criteria of randomized controlled trials can exclude groups of patients indicated for the therapy post-approval and the trial populationmay not be generalizable to routine care.We attempted to emulate the MONALEESA-2 trial of ribociclib plus letrozole for women with advanced breast cancer using real-world data (RWD) to assess the impact of modifying entry criteria of the trial, which found a survival benefit associated with ribociclib (hazard ratio [HR] = 0.76). <b>Materials & methods:</b> Post-menopausal women with recurrent or metastatic breast cancer were identified in a linked electronic health recordsclaims database. Treatment groups were ribociclib plus letrozole or letrozole without ribociclib (referred to as letrozole). Overall survival was compared between the two groups using Cox proportional hazards models with inverse probability of treatment weights and propensity score matching. <b>Results:</b> There were 132,406 patients who initiated ribociclib plus letrozole or letrozole from 13 March 2017 (ribociclib approval) to 30 September 2023. After applying trial entry criteria, the sample size was 3912 patients. Compared with real-world patients, trial participants tended to be younger (&gt;50% were &lt;65 years old compared with 38%) and more commonly had liver or lung metastases (&gt;50% vs &lt;15%). Among realworld patients, those treated with ribociclib plus letrozole had higher comorbidity scores (mean Elixhauser Comorbidity Index Score 15 vs 9) and were more likely to have metastatic disease burden than patients treated with letrozole (85% vs 45%). We were unable to emulate the trial findings; all HRs in this analysis were &gt;1. <b>Conclusion:</b> Real-world patients may differ from those participating in randomized controlled trials. Along with data source limitations, such as missing clinical information or incomplete capture of mortality, this can impact the ability to emulate trials in RWD. However, RWD is key for describing patients in routine care and to answer relevant questions following the approval of new therapies.